 |
1 Disease |  |
22 Trials |
|
22 Trials |  |
183 News |  |
| 123» |
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - Apr 8, 2024
P2, N=92, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2024 --> Mar 2028 | Trial primary completion date: Apr 2024 --> Mar 2028
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Trial completion date, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=83, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment change: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Apr 4, 2024
P2, N=80, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Apr 2024 --> Mar 2028 | Trial primary completion date: Apr 2024 --> Mar 2028 N=55 --> 80
- | Trial completion date, Trial primary completion date: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Mar 17, 2024
P2, N=55, Recruiting, Sponsor: Mayo Clinic
N=55 --> 80 Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
- | alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial completion date, Combination therapy: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 7, 2024
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 2, 2024
P3, N=547, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025 Trial completion date: Jan 2024 --> Jan 2025
- | Venclexta (venetoclax) / Roche, AbbVie, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal: NCI-2023-08755: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 2, 2024
P2, N=0, Withdrawn, Sponsor: Northwestern University
Trial completion date: Jan 2024 --> Jan 2025 N=29 --> 0 | Not yet recruiting --> Withdrawn
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - Feb 19, 2024
P2, N=92, Recruiting, Sponsor: National Cancer Institute (NCI)
N=29 --> 0 | Not yet recruiting --> Withdrawn Suspended --> Recruiting
- | Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
Trial initiation date: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (clinicaltrials.gov) - Feb 16, 2024
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Initiation date: Jul 2024 --> Jan 2024
- | Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
Trial suspension: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P1, N=32, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2024 --> Jan 2024 Recruiting --> Suspended
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Dec 2023 --> Dec 2024
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2024 --> Jan 2025
- || Venclexta (venetoclax) / Roche, AbbVie, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
New P2 trial: NCI-2023-08755: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=29, Not yet recruiting, Sponsor: Northwestern University
- || golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial, CAR T-Cell Therapy: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 17, 2024
P1, N=18, Not yet recruiting, Sponsor: Nathan Denlinger
- | Venclexta (venetoclax) / Roche, AbbVie
Enrollment closed: A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - Dec 18, 2023
P2/3, N=363, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2024 --> Jan 2025 Suspended --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 7, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- | Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (clinicaltrials.gov) - Nov 15, 2023
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Initiation date: Oct 2023 --> Jul 2024 | Trial primary completion date: Mar 2026 --> Oct 2026
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Nov 12, 2023
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Initiation date: Oct 2023 --> Jul 2024 | Trial primary completion date: Mar 2026 --> Oct 2026 Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 28, 2023
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025 Trial completion date: Jun 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- | Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
New P2 trial: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (clinicaltrials.gov) - Jun 2, 2023
P2, N=70, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Polivy (polatuzumab vedotin-piiq) / Roche, parsaclisib (INCB50465) / Incyte, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - May 18, 2023
P1, N=50, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - May 3, 2023
P2, N=71, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Enrollment change: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - May 3, 2023
P2, N=55, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 N=147 --> 55
- | Onureg (azacitidine oral) / BMS
Enrollment open: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 5, 2023
P2/3, N=422, Recruiting, Sponsor: National Cancer Institute (NCI)
N=147 --> 55 Suspended --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 21, 2023
P3, N=529, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial completion date: Jun 2026 --> Mar 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 21, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2026 --> Mar 2024 Trial completion date: Sep 2025 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jul 2023
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 28, 2023
P3, N=547, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2025 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jul 2023 Trial completion date: Jan 2023 --> Jan 2024
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 21, 2023
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2023 --> Jan 2024 Trial completion date: Dec 2022 --> Dec 2023
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Feb 3, 2023
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Jan 2023 --> Jan 2024
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 8, 2022
P3, N=435, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Dec 1, 2022
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2028 --> Dec 2028 | Trial primary completion date: Jun 2028 --> Dec 2028
- Mabtas (rituximab biosimilar) / Intas
Effectiveness and Safety of Rituximab Biosimilar in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results from a Prospective, Multicentre, Real-World Registry Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7458;
This real-world study evaluated the safety and efficacy outcomes of rituximab biosimilar (Mabtas) plus chemotherapy (R-chemo) in Indian patients with B-cell NHL or CLL...Overall, R-chemo was well-tolerated. Conclusion s : Rituximab biosimilar based chemotherapy was effective and safe in real-world clinical practice as the first-line treatment for B-cell NHL and CLL.
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 18, 2022
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Conclusion s : Rituximab biosimilar based chemotherapy was effective and safe in real-world clinical practice as the first-line treatment for B-cell NHL and CLL. Suspended --> Active, not recruiting
- | Onureg (azacitidine oral) / BMS
Trial suspension: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 13, 2022
P2/3, N=422, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Recruiting --> Suspended
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P3 trial: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 14, 2022
P3, N=336, Not yet recruiting, Sponsor: Children's Oncology Group
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 5, 2022
P1, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jun 16, 2022
P1, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Recruiting --> Suspended
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Jun 14, 2022
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - Apr 20, 2022
P2, N=71, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028 Recruiting --> Suspended
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 2, 2022
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2022
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025 Trial completion date: Dec 2021 --> Dec 2022
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Review, Journal: Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union. (Pubmed Central) - Oct 30, 2021
In the EU, pediatric assessments were not required for biosimilars; hence, all biosimilars (except rituximab) have been approved for the same indications as those of the reference biologics. Biosimilar developers need to be aware of the possible requirement of a pediatric study plan, development of pediatric drug delivery devices, and requirement of human factor studies for a device, to avoid delay in approval of biosimilars in the USA.
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - Oct 24, 2021
P2, N=71, Recruiting, Sponsor: National Cancer Institute (NCI)
Biosimilar developers need to be aware of the possible requirement of a pediatric study plan, development of pediatric drug delivery devices, and requirement of human factor studies for a device, to avoid delay in approval of biosimilars in the USA. Suspended --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Sep 1, 2021
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Suspended --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie
Trial suspension: A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - Aug 18, 2021
P2/3, N=374, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov) - Jul 20, 2021
P2, N=68, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Suspended
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 6, 2021
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Suspended Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial primary completion date: Jun 2021 --> Jun 2022
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial suspension, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Jun 28, 2021
P3, N=192, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2021 --> Jun 2022 Recruiting --> Suspended